Trademark: 79097714
Status Date
Monday, December 21, 2020
Filing Date
Tuesday, December 21, 2010
Published for Opposition
Tuesday, July 26, 2011
Abandoned Date
Monday, December 21, 2020
5 Pharmaceuticals for use in stimulating human blood cell production; pharmaceuticals for the treatment of cancer, anemia, ischemia, myocardial infarction, congestive heart failure, renal failure, anoxia-induced cellular degeneration, hypoxia-induced cellular degeneration and stroke
Nov 14, 2021
Notification Of Effect Of Cancellation Of Intl Reg Mailed
Nov 13, 2021
Death Of International Registration
Aug 4, 2016
Abandonment Notice Mailed - Inter Partes Decision
Aug 4, 2016
New Representative At Ib Received
Apr 21, 2014
Limitation From The Ib Examined, No Action Is Needed
Feb 28, 2014
Limitation Of Goods Received From Ib
Jun 2, 2013
Final Decision Transaction Processed By Ib
May 8, 2013
Final Disposition Notice Sent To Ib
May 8, 2013
Final Disposition Notice Created, To Be Sent To Ib
Dec 9, 2012
Limitation Of Goods Received From Ib
May 8, 2012
Abandonment - After Inter Partes Decision
May 8, 2012
Opposition Terminated No. 999999
May 8, 2012
Opposition Sustained No. 999999
Feb 11, 2012
Refusal Processed By Ib
Jan 24, 2012
Opposition Instituted No. 999999
Jan 23, 2012
Opposition Notice (Ib Refusal) Sent To Ib
Jan 21, 2012
Opposition Notice (Ib Refusal) Created
Aug 24, 2011
Extension Of Time To Oppose Received
Jul 26, 2011
Published For Opposition
Jul 6, 2011
Notice Of Publication
Jun 25, 2011
Application Filing Receipt Mailed
Jun 23, 2011
Approved For Pub - Principal Register
Jun 21, 2011
Assigned To Examiner
Jun 21, 2011
New Application Office Supplied Data Entered In Tram
Jun 17, 2011
Sn Assigned For Sect 66a Appl From Ib
Trademark Alertz updated from USPTO on 2030-01-24
